Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19

被引：2
|
作者：
Sookaromdee, Pathum [1 ]
Wiwanitkit, Viroj [2 ,3 ]
机构：
[1] Private Acad Consultant, Bangkok 103300, Thailand
[2] Joseph Ayobabalola Univ, Ikeji Arakeji, Nigeria
[3] Dr DY Patil Univ, Pune, Maharashtra, India
来源：
INFECTION AND CHEMOTHERAPY | 2022年 / 54卷 / 02期
关键词：
D O I：
10.3947/ic.2022.0040
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：369 / 369
页数：1
相关论文
共 50 条
  • [1] Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
    Seo, Hyeonji
    Chong, Yong Pil
    [J]. INFECTION AND CHEMOTHERAPY, 2022, 54 (02): : 370 - 371
  • [2] Fluvoxamine for symptomatic outpatients with COVID-19
    Wu, Peter E.
    Austin, Emily
    Leong, Derek
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (07) : E258 - E258
  • [3] Fluvoxamine for the treatment of COVID-19
    Marzolini, Catia
    Marra, Fiona
    Boyle, Alison
    Khoo, Saye
    Back, David J.
    [J]. LANCET GLOBAL HEALTH, 2022, 10 (03): : E331 - E331
  • [4] Fluvoxamine for the treatment of COVID-19
    Nyirenda, John L. Z.
    Sofroniou, Mario
    Toews, Ingrid
    Mikolajewska, Agata
    Lehane, Cornelius
    Monsef, Ina
    Abu-taha, Aesha
    Maun, Andy
    Stegemann, Miriam
    Schmucker, Christine
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (09):
  • [5] Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial
    Seo, Hyeonji
    Kim, Haein
    Bae, Seongman
    Park, Seonghee
    Chung, Hyemin
    Sung, Heung-Sup
    Jung, Jiwon
    Kim, Min Jae
    Kim, Sung-Han
    Lee, Sang-Oh
    Choi, Sang-Ho
    Kim, Yang Soo
    Son, Ki Young
    Chong, Yong Pil
    [J]. INFECTION AND CHEMOTHERAPY, 2022, 54 (01): : 102 - 113
  • [6] Fluvoxamine for COVID-19 ICU patients?
    Trkulja, Vladimir
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (05) : 2454 - 2455
  • [7] Fluvoxamine for COVID-19?
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2021, 63 (1623): : 69 - 70
  • [8] Fluvoxamine in COVID-19
    Devi, Sharmila
    [J]. LANCET INFECTIOUS DISEASES, 2024, 24 (01): : E23 - E23
  • [9] Trial of fluvoxamine in COVID-19
    Kang, Seema
    [J]. LANCET PSYCHIATRY, 2022, 9 (01): : 17 - 17
  • [10] Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial
    Wannigama, Dhammika Leshan
    Hurst, Cameron
    Phattharapornjaroen, Phatthranit
    Hongsing, Parichart
    Sirichumroonwit, Natchalaikorn
    Chanpiwat, Kanokpoj
    Rad, Ali Hosseini
    Storer, Robin James
    Ounjai, Puey
    Kanthawee, Phitsanuruk
    Ngamwongsatit, Natharin
    Kupwiwat, Rosalyn
    Kupwiwat, Chaisit
    Brimson, James Michael
    Ragupathi, Naveen Kumar Devanga
    Charuluxananan, Somrat
    Leelahavanichkul, Asada
    Kanjanabuch, Talerngsak
    Higgins, Paul G.
    Badavath, Vishnu Nayak
    Amarasiri, Mohan
    Verhasselt, Valerie
    Kicic, Anthony
    Chatsuwan, Tanittha
    Pirzada, Kashif
    Jalali, Farid
    Reiersen, Angela M.
    Abe, Shuichi
    Ishikawa, Hitoshi
    [J]. ECLINICALMEDICINE, 2024, 70
12345